Overview

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors
Phase:
Phase 1
Details
Lead Sponsor:
Birdie Biopharmaceuticals HK Limited
Collaborator:
Seven and Eight Biopharmaceuticals Inc
Treatments:
Antibodies, Monoclonal
Atezolizumab